Immunomodulatory Nanosystems

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2019 Sep 12

PMID 31508270

Citations 140

Authors

Xiangru Feng

Weiguo Xu

Zhongmin Li

Wantong Song

Jianxun Ding

Xuesi Chen

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a variety of diseases, including cancer, infectious diseases, inflammatory diseases, and autoimmune diseases. Immunomodulatory nanosystems can readily improve the therapeutic effects and simultaneously overcome many obstacles facing the treatment method, such as inadequate immune stimulation, off-target side effects, and bioactivity loss of immune agents during circulation. In recent years, researchers have continuously developed nanomaterials with new structures, properties, and functions. This Review provides the most recent advances of nanotechnology for immunostimulation and immunosuppression. In cancer immunotherapy, nanosystems play an essential role in immune cell activation and tumor microenvironment modulation, as well as combination with other antitumor approaches. In infectious diseases, many encouraging outcomes from using nanomaterial vaccines against viral and bacterial infections have been reported. In addition, nanoparticles also potentiate the effects of immunosuppressive immune cells for the treatment of inflammatory and autoimmune diseases. Finally, the challenges and prospects of applying nanotechnology to modulate immunotherapy are discussed.

Citing Articles

Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms.

Wei Q, Liu S, Huang X, Xin H, Ding J Biosaf Health. 2025; 5(1):45-61.

PMID: 40078604 PMC: 11894984. DOI: 10.1016/j.bsheal.2022.11.002.

Nanosystems for modulation of immune responses in periodontal therapy: a mini-review.

Acharya A, Hegde U, Acharya S Front Dent Med. 2025; 5:1509775.

PMID: 39917718 PMC: 11797770. DOI: 10.3389/fdmed.2024.1509775.

Recent nanoengineered therapeutic advancements in sepsis management.

Liu L, Li L, Wang T, Li Z, Yan B, Tan R Front Bioeng Biotechnol. 2024; 12:1495277.

PMID: 39703795 PMC: 11655211. DOI: 10.3389/fbioe.2024.1495277.

Regulation of dynamic spatiotemporal inflammation by nanomaterials in spinal cord injury.

Liu Z, Xiang C, Zhao X, Aizawa T, Niu R, Zhao J J Nanobiotechnology. 2024; 22(1):767.

PMID: 39696584 PMC: 11657436. DOI: 10.1186/s12951-024-03037-8.

Nanolevel Immunomodulators in Sepsis: Novel Roles, Current Perspectives, and Future Directions.

Lin L, Liu H, Zhang D, Du L, Zhang H Int J Nanomedicine. 2024; 19:12529-12556.

PMID: 39606559 PMC: 11600945. DOI: 10.2147/IJN.S496456.

References

Li D, Sun H, Ding J, Tang Z, Zhang Y, Xu W . Polymeric topology and composition constrained polyether-polyester micelles for directional antitumor drug delivery. Acta Biomater. 2013; 9(11):8875-84. DOI: 10.1016/j.actbio.2013.06.041. View

Berinstein N, Karkada M, Morse M, Nemunaitis J, Chatta G, Kaufman H . First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med. 2012; 10:156. PMC: 3479010. DOI: 10.1186/1479-5876-10-156. View

Song W, Shen L, Wang Y, Liu Q, Goodwin T, Li J . Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018; 9(1):2237. PMC: 5993831. DOI: 10.1038/s41467-018-04605-x. View

Dreno B, Thompson J, Smithers B, Santinami M, Jouary T, Gutzmer R . MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 19(7):916-929. DOI: 10.1016/S1470-2045(18)30254-7. View

Warimwe G, Fletcher H, Olotu A, Agnandji S, Hill A, Marsh K . Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data. BMC Med. 2013; 11:184. PMC: 3765422. DOI: 10.1186/1741-7015-11-184. View

Jones R, Mueller S, Kumari S, Vrbanac V, Genel S, Tager A . Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials. 2016; 117:44-53. PMC: 5204257. DOI: 10.1016/j.biomaterials.2016.11.048. View

Hillion J, Smail S, Di Cello F, Belton A, Shah S, Huso T . The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology. 2012; 12(4):372-9. PMC: 3466102. DOI: 10.1016/j.pan.2012.05.005. View

Liu Y, Balachandran Y, Li D, Shao Y, Jiang X . Polyvinylpyrrolidone-Poly(ethylene glycol) Modified Silver Nanorods Can Be a Safe, Noncarrier Adjuvant for HIV Vaccine. ACS Nano. 2016; 10(3):3589-96. DOI: 10.1021/acsnano.5b08025. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

10.

Kim H, Niu L, Larson P, Kucaba T, Murphy K, James B . Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018; 164:38-53. DOI: 10.1016/j.biomaterials.2018.02.034. View

11.

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

12.

Berinstein N, Karkada M, Oza A, Odunsi K, Villella J, Nemunaitis J . Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015; 4(8):e1026529. PMC: 4570133. DOI: 10.1080/2162402X.2015.1026529. View

13.

OHanley P, Lalonde G, Ji G . Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect Immun. 1991; 59(3):1153-61. PMC: 258381. DOI: 10.1128/iai.59.3.1153-1161.1991. View

14.

Nam J, Son S, Ochyl L, Kuai R, Schwendeman A, Moon J . Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018; 9(1):1074. PMC: 5852008. DOI: 10.1038/s41467-018-03473-9. View

15.

Wang C, Ye Y, Hu Q, Bellotti A, Gu Z . Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. Adv Mater. 2017; 29(29). DOI: 10.1002/adma.201606036. View

16.

Witte D, Cunliffe N, Turner A, Ngulube E, Ofori-Anyinam O, Vekemans J . Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi. Pediatr Infect Dis J. 2018; 37(5):483-491. DOI: 10.1097/INF.0000000000001937. View

17.

Song W, Kuang J, Li C, Zhang M, Zheng D, Zeng X . Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication. ACS Nano. 2018; 12(2):1978-1989. DOI: 10.1021/acsnano.7b09112. View

18.

Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke P . Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med. 2016; 8(352):352ra110. PMC: 7780242. DOI: 10.1126/scitranslmed.aaf6843. View

19.

Li S, Zhang Y, Wang J, Zhao Y, Ji T, Zhao X . Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours. Nat Biomed Eng. 2019; 1(8):667-679. DOI: 10.1038/s41551-017-0115-8. View

20.

Gao W, Fang R, Thamphiwatana S, Luk B, Li J, Angsantikul P . Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 2015; 15(2):1403-9. PMC: 4399974. DOI: 10.1021/nl504798g. View